child
UK CF Gene Therapy Consortium

The identification and isolation of the CF gene in 1989 meant that scientists could find ways of correcting the basic CF genetic defect rather than just treating the symptoms of the condition. The best way to do this is through gene therapy - replacing faulty genes with normal ones.

As lung damage is the major cause of illness and death in CF, the first attempts at gene therapy are focusing on delivering genes to the lungs.

UK based researchers have already demonstrated correction of the genetic defect in mice, the human CF nose and, most recently, in the human CF lung. The next step is to try to develop effective treatment for people with CF.

This won't be an easy process. Gene therapy is still in its infancy, and there are many problems to overcome.

The Cystic Fibrosis Trust has brought together the UK's leading CF geneticists to form the UK CF Gene Therapy Consortium. The scientists are based in Edinburgh, London and Oxford.

The Cystic Fibrosis Trust pledged to raise the necessary funds to carry out this work and through the support of the CF community, we have so far invested well over £15 million in this project.

The £15 million has allowed the UK CF Gene Therapy Consortium to develop a lead product comprising the healthy (non-CF) DNA, a carrier to get the gene to the lungs and a promoter to tell the body to turn it on. Further tests for safety and efficiency are being carried out before a single dose trial planned for early 2008 and full multi-dose trials following the results of the single dose pilot study.

It costs around £3.5 million each year to fund the Consortium and it is estimated that the clinical trials will cost at least an additional £6.5 million. The exact amount will depend on the results of the single dose pilot study in early 2008.


lungs
For further information on the work of the UK CF Gene Therapy Consortium, please see CF Today magazine, which is published by the Cystic Fibrosis Trust three times a year. This gives details of recent medical and scientific developments relating to gene therapy and Cystic Fibrosis in a format that can be easily understood. To subscribe to CF Today, please email enquiries@cftrust.org.uk giving your full name and address with a request to be added to the circulation list. The magazine is free of charge and can also be downloaded from our Publications section.